Hepatic Encephalopathy Market, by Drug Class (Antibiotic, Laxatives, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

  • Published On : May 2019 |
  • Pages : 147 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Hepatic Encephalopathy Market – Global Industry Insights

Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the liver disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of ammonia, which can cross the blood–brain barrier and cause significant neurocognitive impairment. A significant number of patients with cirrhosis may experience HE and may be at high risk of recurrent HE.

The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated with high rates of mortality and hospitalizations and poor quality of life. Factors such as infections, gastrointestinal bleeding, metabolic disturbance, and dietary protein overload may cause OHE. According to a study conducted by the U.S. National Library of Medicine in 2016, 30 to 50% of patients who have cirrhosis during their clinical care are likely to develop OHE.

The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026).


Global Hepatic Encephalopathy Market Share (%) By Drug Class, 2018 & 2026

Hepatic Encephalopathy  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing number of drugs in pipeline for the treatment of HE is expected to drive the market growth during the forecast period

There are different types of therapeutic drugs in pipeline for the treatment of HE. Increasing number of products in pipeline for the treatment of HE is expected to drive growth of the market over the forecast period.

Umecrine Cognition, a Sweden-based pharmaceutical company, is developing a therapy that represents a new target class for several major central nervous system (CNS)-related disorders. The lead compound GR3027 is presently in clinical development for HE. The company plans to demonstrate Phase II data of GR3027 for the treatment of HE in 2020.

Rebiotix Inc. is developing the drug: RBX2477 that can be administered orally. The drug is presently under Phase I clinical trial. It is an antibiotic that reduces the production of ammonia by inhibiting growth of ammonia-producing colonic bacteria.

OCR-002 (Ornithine phenylacetate) is an oral drug developed by Ocera Therapeutics Inc. It is presently under Phase I clinical trial. OCR-002 is a small molecule that acts as an ammonia scavenger and decreases the abnormally increasing ammonia.

KLS-13019 is a drug developed by Kanna Life Sciences and is currently under pre-clinical phase. It is a cannabinoid, which acts on cannabinoid receptors in cells that alter the neurotransmitter release inside the brain.

Global Hepatic Encephalopathy Market Share (%) By Distribution Channel, 2018 & 2026

Hepatic Encephalopathy  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of various types of liver diseases is expected to aid in the market growth  

HE is a sign of poor prognosis and correlates with mortality in both patients with acute liver failure and those with cirrhosis associated with end stage liver disease. Liver cirrhosis is a gastroenterological condition that is characterized by a slow, progressive, and irreversible replacement of liver cells by fibrous tissue (scar) that prevents normal liver functioning.

According to the National Center for Biotechnology Information (NCBI): 2014, generally liver cirrhosis affects up to 1% of the U.S. and EU population. Between 180,000 and 290,000 patients with cirrhosis in the U.S. are hospitalized due to complications of HE. Once HE develops, mortality reaches 22-35% after five years. HE is also associated with increased hospitalization and treatment costs. Moreover, subtle signs of HE are observed in around 70% of patients with cirrhosis.

Furthermore, increasing number of liver failure cases is expected to drive growth of the hepatic encephalopathy market over the forecast period. For instance, according to European Association for the Study of the Liver (EASL): 2019, an estimated 170,000 patients die due to liver failure, annually in Europe. During liver failure, an accumulation of protein-bound toxins and increased susceptibility to infection cause multi-organ failure and death.

Moreover, acute liver failure that causes complications such as elevated pressure and excessive bleeding in the brain is known as fulminant hepatic failure that requires emergency hospitalization.

Among regions, North America is expected to be the most lucrative market for hepatic encephalopathy, owing to increasing prevalence of liver diseases in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2017, around 4.5 million adults were diagnosed with liver disease in the U.S. Moreover, the number of deaths due to chronic liver disease and cirrhosis accounted for 40,545 in the U.S. in 2017.  

Moreover, increasing awareness programs for liver disease, liver cancer, and wellness is also expected to boost growth of the market in the U.S. For instance, America Liver Foundation, in partnership with Bayer and Gilead, organizes Liver Cancer Awareness Program annually in the month of October, in U.S. The program focuses on spreading awareness about liver cancer risks and liver wellness.

Key players operating in the global hepatic encephalopathy market include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.

Hepatic encephalopathy (HE) is a common complication of advanced liver disease. HE covers a complex set of non-specific neuropsychiatric symptoms and clinical signs affecting quality of life of patients. HE is a major challenge to the healthcare system due to frequent hospital contacts and admissions. The 2014 AASLD and EASL clinical practice guidelines for managing HE recommend to classify HE according to the underlying liver disease, the severity of the manifestations, the time course, and precipitating factors. HE may be divided into type A that results from acute liver failure, type B that results predominantly from portosystemic encephalopathy (PSS), and type C that results from cirrhosis.

Market Dynamics

HE is a rare disease. Several drugs are available such as antibiotics, laxatives, probiotics, and lactulose that aid in the treatment of this disease. Key players in the market are focused on adopting acquisition strategies to expand their product portfolio. For instance, in December 2017, Mallinckrodt Pharmaceuticals announced acquisition of Ocera Therapeutics, a clinical-stage biopharmaceutical company. Ocera Therapeutics is focused on the development and commercialization of novel therapeutics for orphan and other severe liver diseases.

Hepatic encephalopathy is a syndrome majorly observed in patients suffering from liver cirrhosis, advance liver diseases, and alcohol consumption related cirrhosis. According to the data published in American Liver Foundation in 2017, hepatitis C virus (HCV) infection is the leading cause of liver cirrhosis in the U.S., followed by alcohol consumption related cirrhosis, contributing to around 20% to 25% cases of liver cirrhosis.  

Key features of the study:

  • This report provides in-depth analysis of hepatic encephalopathy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, hepatic encephalopathy drug approval & launch, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hepatic encephalopathy market based on the following parameters – company overview, financial performance, drug portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as part of this study include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, drug distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hepatic encephalopathy market

Detailed Segmentation:

  • Global Hepatic Encephalopathy Market, By Drug Class:
    • Antibiotic
    • Laxatives
    • Others
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies     
  • Global Hepatic Encephalopathy Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • Germany
        • France
        • Italy
        • U.K.
        • Spain
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • South Korea
        • Australia
        • Rest of Asia Pacific
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Antibiotic
        • Laxatives
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • ASKA Pharmaceutical Co., Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Strategies
    • Cosmo Pharmaceuticals N.V.
    • Lupin Limited
    • Kaleido Biosciences
    • Kannalife Sciences, Inc.
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • Umecrine Cognition AB
    • Norgine B.V.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Hepatic Encephalopathy Market, By Drug Class, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Antibiotic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Laxatives
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  5. Global Hepatic Encephalopathy Market, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  6. Global Hepatic Encephalopathy Market, By Region, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • North America
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Region/Country, 2018 - 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Company Profiles
      • ASKA Pharmaceutical Co., Ltd.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Cosmo Pharmaceuticals N.V.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Lupin Limited
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Kaleido Biosciences
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Kannalife Sciences, Inc.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Ferring Pharmaceuticals Inc.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Umecrine Cognition AB
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Norgine B.V.
        • Company Overview
        • Source Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 26 figures on "Hepatic Encephalopathy Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.